On September 20, 2016, First China Drug Regulation Scientific Congress was held in Beijing with the theme of “Reform and Innovation in Drug Regulation”. Bi Jingquan, director general of CFDA attended the congress and made a speech.

Bi Jingquan stressed that the Party Central Committee and the State Council attached great importance to drug regulation. As a special commodity for medical treatment, drug regulation shall follow objective laws. Based on good understanding and application of laws and rules, we shall make further reform and innovation, consistently promote the scientific regulation, and earnestly ensure people's life security and health.

This congress is sponsored by China Society for Drug Regulation. At the congress, Shao Mingli, president of China Society for Drug Regulation proposed among nearly a thousand “pharmaceutical staff” present at the congress that individuals engaged or to be engaged in drug research, production, sales, use, evaluation and regulation shall assume financial, legal, social and political responsibilities in their career of protecting public health and drug safety & effectiveness. “Pharmaceutical staff” shall effectively protect the legitimate rights and interests of manufacturers, create a competitive and orderly social environment, and shall master scientific knowledge of the most advanced, most cutting-edged and most practical as well as technical measures, and establish a scientific regulatory system.

Provincial and municipal food and drug administrations and technology support departments, along with domestic and foreign academicians, experts, scholars and entrepreneurs in the pharmaceutical field, interpreted and discussed difficulties and hot issues encountered during the implementation of a series of initiatives of drug regulatory reforms and innovative medical development at present. The congress will build a driving, influential and vigorous platform for high-level academic exchanges and collaborations through drug regulation. Seven sub-forums were held alongside the main forum, including medical quality supervision and medical safety and effectiveness sub-forums, sub-forums for interpretation of policies and regulations on pharmaceutical adjuvants and drug packing materials, and medical device scientific regulatory sub-forum.

Leaders of CAMDI were also invited to attend this congress.